Algernon Pharmaceuticals Inc (AGNPF)

[GVX808]

Ok, I'm pretty sure you asked this question last night, so I'm only doing this to prevent you from asking again. However, your question has been answered across many forums and in many forms over the past few weeks.
- I hope and assume you are reading all of the news releases, new articles and watching the Proactive videos, Biopub videos, various news clips, etc... like the rest of us.
- Reading message boards is important also, but should be last on the list of importance. Put simply, you should not be getting your news or making investment decisions from what you read on message boards.

The answer to your questions was originally answered in the news releases on:

Feb 17:

"The database will be locked for analysis on March 5th and the Company will update the market on the final data release shortly thereafter."

https://www.globenewswire.com/news-release/2021/02/17/2177029/0/en/Algernon-Pharmaceuticals-Provides-Update-on-COVID-19-Phase-2b-Final-Study-Data.html

...and..

Jan 07:

"The Company has projected that the final data set for the Phase 2b part of its Phase 2b/3 clinical trial from its Ifenprodil COVID-19 clinical study will be available by the end of February 2021. If the data is positive, the Company will consult with the U.S. FDA on an Emergency Use Authorization (EUA).

The Company will also evaluate all aspects of conducting a Phase 3 trial, which will be required regardless of whether or not the Company receives an EUA."

https://www.globenewswire.com/news-release/2021/01/07/2154898/0/en/Algernon-Pharmaceuticals-Announces-Plans-for-2021.html


This same info has also been talked about by Chris Moreau (he's the CEO of Algernon), in many Proactive and BioPub videos.

As a matter of fact, just yesterday, on the DMT BioPub video, Chris Moreau mentioned again that the database will be locked for analysis this Friday (March 5th) and at that point everyone (including Algernon execs) wait on the FDA to make their decision. No one knows what the decision is going to be or when the results of their decision will be revealed. What WE DO know is that it will be released "shortly thereafter".


Lastly, it has been mentioned on this message board numerous times. It was actually mentioned in the last couple weeks on this message board, if you happen to be following along.

Heck, even MoneyS talked about it yesterday in a message:

He quoted the Feb 17th news release and then stated:

"I'll be the first to say here - my best guess is the analysis of Phase 2b data and subsequent readout will take 4 to 6 weeks. I'm expecting the readout around April 15th - USA Tax Day."

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162281615


So, as you can see, no one knows how long "shortly thereafter" is going to take.
We are all hoping it will be only a fews days or a week, but the reality may be 2, 3, or 4 weeks.
It is a waiting game at this point until the FDA analyzes the data and complete their report.

Hopefully the report is a very positive one that results in an Emergency Use Authorization (EUA).

Good luck.